Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Different desensitization strategies are available for treating patients with preformed human leukocyte antigen (HLA) antibodies. A highly presensitized heart recipient received immunoadsorption and rituximab therapy. The patient, with end-stage heart failure, was positive only for antibodies of HLA class I (anti-A2, A10, B17), and Luminex platform (One Lambda kit) showed a panel-reactive antibody score of 64%. The patient's serum was tested repeatedly in both complement-dependent cytotoxicity and flow-cytometry crossmatches against cells from different potential organ donors. The results of these crossmatches were positive on flow cytometry when tested with HLA-A2, A10, and B17 but were still negative on cytotoxicity. The patient was treated with a desensitization regimen; this treatment immediately decreased antibody levels of 70% and the patient subsequently received a transplant with donor-specific HLA antibody (HLA-A2). After more than 2 years, graft function remains normal and the clinical status of the patient is stable.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7182/pit2013454 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the Role of Extracorporeal Photopheresis in Kidney Transplant Management.
Transplant Direct
September 2025
Laboratori Experimental de Nefrologia i Trasplantament (LENIT), Fundació de Recerca Clinic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain.
Extracorporeal photopheresis (ECP) is emerging as an apoptotic cell-based therapy that suppresses alloimmunity, promotes donor-specific regulation, and reduces the need for conventional maintenance immunosuppression. ECP therapy is associated with regulatory T-cell proliferation, anti-inflammatory effects, and reduction of anti-HLA antibodies, making ECP a possible alternative or adjunct treatment for preventing and treating transplant rejection. Presently, we have a limited understanding of the mechanisms of ECP action, and clinical evidence for efficacy in kidney transplantation is sparse.
View Article and Find Full Text PDFPre-transplant compatibility testing: Transition from CDCXM to flow cytometry in India.
Transpl Immunol
September 2025
Molecular and Transplant Immunology Laboratory, Department of Transfusion Medicine (Blood Center), Medanta-The Medicity, Gurgaon, Haryana, India.
Over 60 % of kidney transplant candidates are non-sensitised while remaining 40 % are sensitised because of previous exposure to human alloantigens during previous transplants, blood transfusions, and pregnancy in women. Pre-transplant compatibility testing is mandatory prior to renal transplantation for detecting the presence of donor-specific antibodies (DSAs), which are associated with early hyperacute/acute and later chronic rejections. Initially, complement-dependent cytotoxicity crossmatch (CDCXM) was used as a traditional method for detecting preformed DSAs.
View Article and Find Full Text PDFFirst use of imlifidase desensitization in a highly sensitized heart and liver transplant candidate: A case report.
Hum Immunol
September 2025
Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
Heart transplant candidates that are highly sensitized against human leukocyte antigens (HLA) face ongoing challenge in finding immunologically compatible donors. Desensitization strategies aimed at reducing HLA antibody titers have variable success rates. Imlifidase, a novel immunoglobulin G-degrading enzyme derived from Streptococcus pyogenes has been successfully used to eliminate pre-formed antibodies in sensitized kidney transplant recipients.
View Article and Find Full Text PDFBiomarker-Based Surveillance in Heart Transplant Rejection.
Can J Cardiol
September 2025
Division of Cardiology, Hartford HealthCare Heart and Vascular Institute, Hartford, CT, USA. Electronic address:
Post-transplant rejection surveillance remains a cornerstone of heart transplant care. Although endomyocardial biopsy (EMB) has long been the gold standard for detecting rejection, its invasive nature, interobserver variability in histologic interpretation, and limitations in distinguishing between acute cellular rejection (ACR) and antibody-mediated rejection have prompted interest in noninvasive techniques. Traditional biomarkers- such as troponin, C-reactive protein, brain natriuretic peptide, and donor-specific antibodies- offer supplementary assessments of graft function but lack the specificity and sensitivity required to be standalone markers.
View Article and Find Full Text PDFAssessing the adequacy of immunosuppression in pediatric liver transplantation with immune Monitoring: Are we there yet?
Hum Immunol
September 2025
MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC, USA. Electronic address:
Current approaches used for pediatric liver transplant (LT) surveillance have diagnostic limitations. We used pleximmune™ immune reactivity index (IRI) and anti-HLA donor specific antibody (DSA) to predict the adequacy of immunosuppression (IS) relative to risk of acute cellular rejection (ACR) at 1-year post LT. This is a retrospective chart review of children who underwent LT between January 1, 2016, through December 31, 2020, and had at least one pleximmune measurement performed within 60-days of a liver biopsy.
View Article and Find Full Text PDF